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DERIVATION OF ENDOTHELIAL COLONY FORMING CELLS FROM HUMAN 
CORD BLOOD AND EMBRYONIC STEM CELLS 
 
Endothelial Colony Forming Cells (ECFCs) are highly proliferative endothelial 
progenitor cells with clonal proliferative potential and in vivo vessel forming ability. 
While endothelial cells have been derived from human induced pluripotent stem cells 
(hiPS) or human embryonic stem cells (hES), they are not highly proliferative and require 
ectopic expression of a TGFβ inhibitor to restrict plasticity. Neuropilin-1 (NRP-1) has 
been reported to identify the emergence of endothelial precursor cells from human and 
mouse ES cells undergoing endothelial differentiation. However, the protocol used in that 
study was not well defined, used uncharacterized neuronal induction reagents in the 
culture medium, and failed to fully characterize the endothelial cells derived. We 
hypothesize that NRP-1 expression is critical for the emergence of stable endothelial cells 
with ECFC properties from hES cells. We developed a novel serum and feeder free 
defined endothelial differentiation protocol to induce stable endothelial cells possessing 
cells with cord blood ECFC-like properties from hES cells. We have shown that Day 12 
hES cell-derived endothelial cells express the endothelial markers CD31+ NRP-1+, 
exhibit high proliferative potential at a single cell level, and display robust in vivo vessel 
forming ability similar to that of cord blood-derived ECFCs. The efficient production of 
the ECFCs from hES cells is 6 logs higher with this protocol than any previously 
published method. These results demonstrate progress towards differentiating ECFC from 
vi 
 
hES and may provide patients with stable autologous cells capable of repairing injured, 
dysfunctional, or senescent vasculature if these findings can be repeated with hiPS. 
 
Mervin C. Yoder MD, Chair 
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INTRODUCTION 
  
2 
Endothelial colony forming cells (ECFCs) are rare circulating endothelial cells 
with robust clonal proliferative potential that display intrinsic in vivo vessel forming 
ability[1-7]. ECFCs, also called blood outgrowth endothelial cells (BOEC)[8], have been 
shown to be directly transplantable in sex-mismatched human bone marrow transplant 
patients with the most proliferative circulating BOEC displaying genetic marking of the 
donor marrow[8, 9]. While this study undoubtedly proves the direct transplantable nature 
of these cells (without any intervening period of in vitro culture), it does not fully explain 
the cell of origin within the transplanted donor marrow that gives rise to the BOEC, the 
engraftment site of the BOEC in the host, or the mechanisms with which the cells are 
mobilized into the systemic circulation. Given the known residence of ECFC within the 
vascular endothelial intima[3], it is plausible that blood vessel endothelial cells may be 
the resident niche for the circulating ECFC. ECFC rapidly mobilize into the blood stream 
following an experimental myocardial ischemic event[10] and in human subjects, the 
concentration of circulating ECFC correlates with the severity of coronary artery 
occlusion and chronic myocardial ischemia[11, 12]. When cultured ECFCs are injected 
intravenously into rodent vascular injury models, they are rapidly recruited into the site of 
vascular injury or tissue ischemia to orchestrate the initiation of a vasculogenic 
response[13-17]. In numerous animal models of human disease, ECFCs have been 
reported to enhance vascular repair and improve blood flow following myocardial 
infarction[18, 19], stroke[13], ischemic retinopathy[20, 21], ischemic limb injury[14-17], 
and to engraft and re-endothelialize denuded vascular segments or implanted grafts. The 
ability to increase the microvascular density within these regenerating tissues heralds 
ECFC as one of the most promising cell-based strategies for therapeutic 
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revascularization. While cultured and implanted ECFCs form durable and functional 
human blood vessels in vivo, they are rare in number in peripheral blood (1/107-108 
peripheral blood mononuclear cells)[1, 2, 8, 12, 22, 23] and their number tends to decline 
with age and disease in human[11, 24, 25] and non-human primates[26]. In elderly 
patients and subjects with peripheral arterial disease (PAD) and critical limb ischemia 
(CLI), circulating or resident ECFC may become prone to replicative senescence lacking 
proliferative potential, thus, rendering them impotent for autologous vascular repair. 
Thus, it is necessary to find an alternate source of healthy ECFCs that may be used for 
vascular repair in these subjects.  
Human pluripotent stem cells (human embryonic stem [hES] and induced 
pluripotent stem [hiPS] cells) display virtually unlimited self-renewal capacity and ability 
to differentiate into any cell types in our body[27-29] and these cells offer the opportunity 
to derive ECFC for vascular repair. Both hES and hiPS cells have been reported to 
differentiate into cells of the endothelial lineage[30-42], however the derived endothelial 
cells are in some cases, unstable and are reported to drift to various non-endothelial 
phenotypes[34, 43] or exhibit low proliferative potential with a proclivity to reach 
replicative senescence within 5-7 passages[43-45]. Indeed, there is no published evidence 
for derivation of ECFC that display the properties of high clonal proliferative potential 
with in vivo vessel forming capacity from hES or hiPS cells. 
Here we describe a novel hES cell differentiation protocol that can reproducibly 
generate a homogenous and stable population of endothelial cells with ECFC properties 
that are similar to cord blood ECFC. With our simple one step 2D serum- and stromal 
cell-free differentiation protocol, we were able to consistently generate over a trillion 
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endothelial cells in less than 3 months of culture; an efficiency that has not been 
approached by any of the previously published endothelial differentiation protocols. This 
method involves initiation of endothelial lineage differentiation by growing hPS cells in 
serum-free endothelial differentiation media supplemented with growth factors for 12 
days on Matrigel coated dishes. On day 12, cells were harvested and sorted using 
antibodies that recognize several well-established endothelial antigens. Only the NRP-
1+CD31+ subset of cells exhibited ECFC properties, including robust in vivo vessel 
formation when implanted in immune-deficient mice. These ECFCs were not 
transformed and could be implanted for >3 months without evidence of teratoma 
formation. We have also determined that KDR activation via addition of a NRP-1-Fc 
dimer and VEGF165 is required for the derivation and emergence of ECFCs from hES 
cells. Overall, our studies reveal a novel paradigm for derivation of endothelial cells with 
ECFC properties from hES cells via activation of a specific molecular pathway. Our 
innovative strategy to produce clinically relevant numbers of ECFC with in vivo vessel 
forming cell potential should be tested in hiPS cells and if successful, may soon permit 
trials to regenerate the deficient microvasculature that may underlie the most prominent 
deficit for vascular repair in patients with cardiovascular disease.  
 
Novel Endothelial Colony Forming Cell Marker 
Vascular endothelial cadherin (CD144) was at one time thought to be a specific 
marker for vascular endothelial cells. However it has since been discovered that CD144 is 
present on other cell types as well, such as hematopoietic cells[46]. Previous publications 
on the derivation of endothelial cells employed the use of this marker to isolate the 
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endothelial cell types. Possibly extraneous cell types may have been isolated using this 
process and restricted the ability of cells to reinforce cellular signaling and fully commit 
the endothelial lineage. Because of their use of this marker inhibitors were necessary to 
maintain the desired phenotype. Thus we set out to use a novel marker for the isolation of 
ECFCs. 
Neuropilin1 (NRP-1) is a VEGF coreceptor which is able to synergistically 
upregulate the downstream signaling of some VEGF receptors[47]. NRP-1 homozygous 
deficient mice demonstrate greatly diminished yolk sac vasculature, disorganized somatic 
blood vessels, and this defect results in embryonic lethality by E12.5-13.5. In 2009 
Cimato et al reported that NRP-1 was an early marker for endothelial cells predating 
CD144 expression during endothelial cell differentiation from hES cells[33]. It has also 
been shown that NRP-1 is crucial for the development of vascular endothelial cells. We 
set out to use NRP-1 antibodies in concert with other known endothelial antigens to 
develop a system to specifically isolate endothelial cells. While we show NRP-1 to be 
essential for the specification of ECFCs it does not appear to be necessary for the 
maintenance of the ECFC lineage and is not correlated with proliferative capacity in later 
passages. 
 
Aim of this Study 
Our primary goal was to obtain highly proliferative endothelial cells with all of 
the ECFC hallmarks. This goal required that I verify the techniques in which ECFCs are 
obtained and characterized from human umbilical cord blood. I was fortunate to be 
involved with writing a review protocol on the isolation, expansion, and characterization 
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of ECFCs during my first few months in the lab. This review was published in the 
Journal of Visualized Experiments. This publication allowed me to perfect the techniques 
necessary to perform my work on our current project, which will be submitted soon. 
Chapter I discusses the isolation, derivation, and characterization of cord blood 
derived ECFCs. We report optimized procedures for extracting ECFCs from Cord blood, 
methods to culture and purify a homogenous population of ECFCs, and provide protocols 
to characterize ECFC functions in vitro and in vivo. This work provides the foundation 
and basis of comparison for all subsequent work on deriving ECFCs from hPS cells. 
Chapter II discusses the major focus of my work on developing and optimizing a 
novel protocol for isolating, expanding, and characterizing hES derived ECFCs. By 
modifying several existing protocols we developed a novel robust protocol to efficiently 
isolate ECFCs with stable phenotypes through many passages without loss of functions 
including in vivo vessel forming potential. To date this is the only protocol for deriving 
stable highly proliferative ECFCs from pluripotent stem cells. 
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Chapter I: Phenotypic and Functional Characterization of Endothelial Colony 
Forming Cells Derived from Human Umbilical Cord Blood 
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Abstract  
Longstanding views of new blood vessel formation via angiogenesis, 
vasculogenesis, and arteriogenesis have been recently reviewed[48]. The presence of 
circulating endothelial progenitor cells (EPCs) were first identified in adult human 
peripheral blood by Asahara et al. in 1997[49] bringing an infusion of new hypotheses 
and strategies for vascular regeneration and repair. EPCs are rare but normal components 
of circulating blood that serve as sites of blood vessel formation or vascular remodeling, 
and facilitate either postnatal vasculogeneis, angiogenesis, or arteriogenesis largely via 
paracrine stimulation of existing vessel wall derived cells[50]. No specific marker to 
identify an EPC has been identified, and at present the focus of the field is to understand 
that numerous cell types including proangiogenic hematopoietic stem and progenitor 
cells, circulating angiogenic cells, Tie2+ monocytes, myeloid progenitor cells, tumor 
associated macrophages, and M2 activated macrophages participate in stimulating the 
angiogenic process in a variety of preclinical animal model systems and in human 
subjects in numerous disease states[51, 52]. Endothelial colony forming cells (ECFCs) 
are rare, circulating viable endothelial cells characterized by robust clonal proliferative 
potential, secondary and tertiary colony forming ability upon replating, the ability to form 
intrinsic in vivo vessels upon transplantation into immunodeficient mice[1-3]. While 
ECFCs have been successfully isolated from the peripheral blood of healthy adult 
subjects, umbilical cord blood (CB) of healthy newborn infants, and vessel wall of 
numerous human arterial and venous vessels [1-3, 53], CB possesses the highest 
frequency of ECFCs[1] that display the most robust clonal proliferative potential and 
form durable and functional blood vessels in vivo[2, 4-7]. While the derivation of ECFCs 
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from adult peripheral blood has been presented[8, 54], we describe the methodologies for 
the derivation, cloning, expansion, and in vitro as well as in vivo characterization of 
ECFCs from human umbilical CB.  
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Reagents and Solutions 
 
EGM-2 media (Lonza, Cat. No. cc-3162 containing EBM-2 basal medium and EGM-
2 SingleQuot kit Supplements, and growth factors) 
EBM-2 (Lonza, Cat. No. cc-3156) supplemented with the entire singlequot 
kit supplements and growth factors (Lonza, Cat. No. cc-4176), 10% (v/v) fetal 
bovine serum (FBS) and 1% (v/v) penicillin (10,000 U/ml)/streptomycin (10,000 
µg/ml)/amphotericin (25 µg/ml). Store up to 1 month at 4˚C. Recommended 
EGM-2 volumes to use for ECFC culture are 500 µl/well for 24-well plates, 2 
ml/well for 6-well plates, 5 ml/25-cm2 flasks, and 10 ml/75-cm2 flasks, unless 
otherwise specified in the protocol. 
 
Collagen I solution 
Dilute 0.575 ml of glacial acetic acid (17.4 N) in 495 ml of sterile distilled 
water (0.02 N final concentration). Sterile filter the dilute acetic acid with a 0.22-
µm vacuum filtration system. Add 25 mg rat tail collagen I to the dilute acetic 
acid to a final concentration of 50 µg/ml. The amount of collagen added will vary 
depending on the collagen stock concentration. Store up to a month at 4˚C.  
 
Preparation of collagen I-coated tissue culture surfaces 
Place 1 ml of collagen I solution in each well of a 6-well tissue culture 
plate (use 300 µl/well for 24-well plates, 3 ml/25-cm2 flasks, and 8 ml/75-cm2 
flasks). Incubate 1 hour to overnight at 37˚C. Remove the collagen I solution and 
11 
wash surface two times, each time with PBS (use 500 µl/well for 24-well plates, 2 
ml/well for 6-well plates, 5 ml/25-cm2 flasks, and 10 ml/75-cm2 flasks). Use 
plates immediately for cell cultures. 
 
FACS staining buffer 
Phosphate-buffered saline (PBS) supplemented with 2% (v/v) fetal bovine 
serum (FBS). Store up to 2 weeks at 4˚C. 
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Name of the reagent Company Catalogue Number 
Heparin Sodium Injection, USP APP Pharmaceuticals 504031 
Ficoll-Pague Amersham Biosciences 17-1440-03 
Mixing cannula Maersk Medical 500.11.012 
EGM-2 Lonza CC-3162 
Defined FBS Hyclone SH30070.03 
TrypLE express Gibco 12605 
Rat type I collagen BD Biosciences 354236 
Matrigel BD Biosciences 356234 
FcR Block Miltenyi Biotech 130-059-901 
hCD31, FITC conjugated BD Pharmingen 555445 
hCD45, FITC conjugated BD Pharmingen 555482 
hCD14, FITC conjugated BD Pharmingen 555397 
hCD144, PE conjugated eBioscience 12-1449-80 
hCD146, PE conjugated BD Pharmingen 550315 
hCD105, PE conjugated Invitrogen MHCD10504 
Ms IgG1,k antibody, FITC conjugated BD Pharmingen 555748 
Ms IgG1,k antibody, PE conjugated BD Pharmingen 559320 
Ms IgG2a,k antibody, FITC con. BD Pharmingen 555573 
Anti-human CD31 Dako clone JC70/A 
Anti-mouse CD31 BD Pharmingen 553370 
0.22-µm vacuum filtration system Millipore SCGPU05RE 
Glacial acetic acid, 17.4N Fisher A38-500 
Antibiotic-Antimycotic Invitrogen 15240-062 
Fetal bovine serum (FBS) Hyclone SH30070.03 
IHC Zinc Fixative  BD Biosciences  550523 
Sytox green reagent Invitrogen S33025 
Cloning cylinders, sterile Fisher Scientific  07-907-10 
 
Table 1. Reagent List   
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Protocol Text  
 
A.) ECFC Outgrowth, Cloning and Expansion 
A.1.1) Collect CB with heparin (10 U heparin/ml blood) or EDTA as an anticoagulant 
and transport to the laboratory at room temperature and immediately (within 2 hours of 
infant’s delivery) process the sample for mononuclear cell (MNC) isolation. 
A.1.2) Aliquot 15 ml of CB into each 50-ml conical centrifuge tube and add 20 ml of 
PBS to each tube of CB and pipet several times to mix. Draw up 15 ml Ficoll-Paque into 
a 20-ml syringe and attach a 20G needle or mixing cannula. Place the tip of the mixing 
cannula at the bottom of the tube of diluted blood and carefully underlay 15 ml Ficoll-
Paque. Centrifuge the tubes 30 min at 740 x g, at room temperature, without the 
deceleration brake setting.  
A.1.3) Using a transfer pipet, remove the hazy layer of low-density MNCs located at the 
interface between the Ficoll-Paque and diluted plasma. Dispense the MNCs into a 50-ml 
conical tube containing 10 ml EGM-2 medium. Centrifuge the MNCs 10 min at 515 x g, 
at room temperature, with a high deceleration brake setting. 
A.1.4) Carefully aspirate and discard the supernatant. Wash the pelleted cells with EGM-
2 twice (10 min at 515 x g) and re-suspend the MNCs in EGM-2 at 1.25 x 107 cells/ml. 
Prepare collagen I coated 6-well tissue culture plates by adding 1 ml rat-tail collagen type 
I (50 µg/ml) per well and incubating the plate overnight. Pipet 4 ml of this MNC 
suspension into each well and place the cells in 37˚C, 5% CO2 humidified incubator. 
A.1.5) After 24 hours (day 1), slowly remove the spent medium (do not disturb the 
loosely adherent cells) from the well with a pipet, slowly add 4 ml EGM-2 to the well, 
14 
and return plate to the incubator. On day 2, refresh the medium by slowly removing the 
medium (do not disturb the loosely adherent cells) from the well with a pipet and adding 
4 ml EGM-2 to each well. Repeat the medium change daily until day 7 and every other 
day thereafter until ECFC colonies appear for cloning. Typically colonies appear between 
day 5 and day 14[1] (Fig. 1). 
A.2.1) Visualize typical ECFC colonies with cobblestone morphology using inverted 
microscope (magnification 10x) and mark the colony boundaries with a marker on the 
underside of the well to indicate the position of each colony.  
A.2.2) On day 14, wash these primary colonies 2 times with PBS and harvest individual 
colonies using cloning cylinders and just enough TrypLE express to cover the cells inside 
the cylinders. After aspirating the final wash of PBS, place a sterile gel coated cloning 
cylinder around each colony and press firmly against the plate using sterile forceps. Add 
2-3 drops of warm TrypLE express into each cloning cylinder and incubate for 3-5 min 
until cells within the cylinder begin to detach. Add approximately 250 µl EGM-2 
medium into the center of the cylinder and pipet up and down to generate single cell 
suspension. Transfer the single cell suspension from each cloning cylinder separately into 
an individual micro-centrifuge tube.  
A.2.3)Wash the area within the cylinder 2-3 times with approximately 250 µl EGM-2 
medium to collect all remaining cells and transfer the wash from each cylinder into the 
respective micro-centrifuge tube. Centrifuge the cells at high speed (≤300 x g) on 
tabletop centrifuge for 5 min. 
A.2.4) Remove the supernatant and re-suspend the cell pellet in 1.5 ml fresh EGM-2 
medium. Transfer the cell suspension (containing all the cells from individual colonies) 
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from each tube into one well of a 24-well tissue culture plate pre-coated with 500 µL rat-
tail collagen I (50 µg/ml).  
A.2.5) Place inside the incubator for expansion with media change performed every other 
day.  
A.3.1) When cells approach 80-90% confluency, remove the spent medium then wash the 
cells 2 times with PBS and add 500 µl TrypLE express medium to each well of 24-well 
tissue culture plate. Place the plate inside the incubator for 3-5 min until cells begin to 
round up and detach. Add 1 ml of EGM-2 (with 10% defined FBS) to each well to collect 
the cells by washing and transfer them to a 15 ml tube. Wash the well with 1 ml EGM-2 
medium to collect all remaining cells and transfer the wash from each well into respective 
15 ml tube. Centrifuge the cells at 300 x g for 5 min. 
A.3.2) Remove the medium and re-suspend the cell pellet in 1 ml fresh EGM-2 medium 
(with 10% defined FBS). Obtain the viable cell count of an aliquot using a 
hemacytometer and trypan blue exclusion.  
A.3.3) Expand the cells by seeding about 5000 cells/cm2 onto a collagen I pre-coated 
tissue culture surfaces in EGM-2 media with media change every other day until cells 
approach 80-90% confluency before sub-culturing again.  
 
B.) In vitro phenotypic characterization of ECFCs: Endothelial cell surface antigen 
expression and single cell assay for clonal proliferative potential  
B.1.1) For endothelial cell surface antigen expression, detach cells with TrypLE express 
to collect cells by using methods described for ECFC cloning and expansion.  
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B.1.2) Re-suspend cells in FACS staining buffer (10 X 106 cells/ 1 ml FACS staining 
buffer) then add FcR blocking reagent (20 µl/ 10 X 106 cells), mix gently and place on 
ice for 10 min.  
B.1.3) Aliquot 100 µl of this cell suspension in micro-centrifuge tube for each endothelial 
surface antigen and isotype controls. Add appropriate amount of fluorochrome labeled 
human monoclonal antibodies that recognize endothelial antigens (CD31, CD144, 
CD146, and CD105) or hematopoietic antigens (CD45, and CD14) and leave on ice for 
30 min protected from light. Caution: 1 X 106 cells are not required for each test. The 
authors typically prepare 0.5 to 1 X 105 cells/tube to obtain 2 X 104 analyzed events. 
Also, follow the manufacturer’s recommendation for the amount of antibody to be used 
for each test. Some antibodies may require titrating to determine the optimal antibody 
concentration. All staining that the authors have performed are single color staining.  
B.1.4) After 30 min of incubation on ice, centrifuge each tube at high speed on a tabletop 
centrifuge for 5 min then remove the supernatant and re-suspend the cell pellet in FACS 
buffer. 
B.1.5) Analyze the samples on a flow cytometer to determine the percentage of cells that 
stain positively or negatively for each antigen. ECFCs stain uniformly positive for CD31, 
CD144, and CD146, but negative for CD45 and CD14 compared to the corresponding 
isotype controls. 
B.2.1) For single cell assay to examine the clonal proliferative potential, detach early 
passage (2-3) cells with TrypLE express to collect cells using methods similar to that was 
described for ECFC cloning and expansion.  
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B.2.2) Infect these cells with enhanced green fluorescent protein (EGFP) expressing 
lentiviruses[55] and collect cells expressing EGFP by fluorescence cytometry. Caution: 
Working with lentvirus is considered a biohazard and all bio-safety precautions should 
be obeyed.  
B.2.3) Culture them as described for culturing ECFC in the section for ECFC expansion.  
B.2.4) Prepare Collagen I coated 96-well plates by adding 50 µl rat-tail collagen type I 
(50 µg/ml) per well and incubate the plate for overnight. Collect the EGFP+ ECFCs by 
using TrypLE express and resuspend them in EGM-2 medium with final concentration 
~106 cells /ml. 
B.2.5) Use FACS Vantage (Becton Dickson) or other comparable sorter with low flow 
rate of 20 cells/second to sort one single EGFP+ ECFC per well of a 96-well plate and 
adjust the final volume to 200 µl per well with EGM-2. Use an inverted fluorescence 
microscope to ensure that each well received only one cell. Alternatively, single cells can 
be sorted based on FSC and SSC and Sytox nuclear dye staining the colonies can be used 
for cell scoring and quantification. 
B.2.6) Incubate the plate over a period of two weeks with two media changes (200 µl 
EGM-2 using multichannel pipetter) performed on day 5 and day 10. On day 14 of 
culture, wash each well with 100 µl PBS before fixing the cells with 100 µl of 4% 
paraformaldehyde for 30 min. For ECFCs that are not expressing EGFP, add Sytox 
reagent, a green fluorescent nuclear dye, following paraformaldehyde fixation and 
incubate at 4 ˚C overnight.  
B.2.7) Use a fluorescence microscope to examine each well to quantitate the number of 
endothelial cells that expanded from a single cell cultured for 14 days. For quantitative 
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analysis, score wells with 2 or more endothelial cells as positive (for proliferation) and 
examine them further for total endothelial cell count by visual counting with the 
fluorescence microscope.  
B.2.8) To display the obtained data, wells with an endothelial cell number of: 2 to 50, 51-
2000, and 2001 or more, are considered as: endothelial cell clusters, low proliferative 
potential (LPP)-ECFCs, and high proliferative potential (HPP)-ECFCs respectively. 
ECFCs exhibit complete hierarchy of clonal proliferative potential by giving rise to 
endothelial clusters, LPPs, and HPPs when cultured at a single cell level for 14 days[1]. 
 
C.) In vivo functional characterization of ECFCs: in vivo vessel formation assay to 
examine the ECFC’s potential for vasculogenesis 
C.1.1) Prepare cellularized gel implants by calculating the total volume (ml) of each of 
the following gel materials (with the final concentration in the parenthesis) needed to cast 
1-ml gel (which will be later bisected to generate 2 implants): FBS (10%), EBM-2 10:1 
(adjust the final volume to 1 ml), sodium bicarbonate (1.5 mg/ml), NaOH (adjust pH to 
7.4), HEPES (25 mM), fibronectin (100 µg/ml), and collagen I (1.5 mg/ml).  
C.1.2) After gel material calculation, detach cells with TrypLE express to collect cells 
using methods similar to that was described for ECFC cloning and expansion. Obtain a 
viable cell count of an aliquot using a hemacytometer and trypan blue. Transfer 2.4 
million viable cells into a 50 ml-conical tube and pellet the cells by centrifugation at 515 
x g, room temperature. Simultaneously, prepare gel matrix solution by adding calculated 
volumes of HEPES, sodium bicarbonate, EBM-2 10:1, FBS, fibronectin, and collagen to 
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an ice-cold 50-ml conical tube (in the same order as they are listed). Mix thoroughly and 
adjust the pH to 7.4 with NaOH while keeping solution on ice.  
C.1.3) Discard the supernatant from the cells after centrifugation and re-suspend the 
pellet in 360 µl warm EGM-2 and to it add pH adjusted 840 µl of gel matrix solution, 
making the final volume of gel implant 1 ml. Mix the cells into gel matrix solution slowly 
until cells are thoroughly suspended in the gel solution.  
C.1.4) Transfer this 1 ml cellularized gel suspension to one well of a 12-well tissue 
culture plate and incubate for 20-30 min until the gel polymerizes. Gently cover the gel 
with 2 ml warm EGM-2 and incubate overnight.  
C.1.5) Immediately before the implantation, bisect the overnight incubated gel into two 
equal pieces using iris scissors and return the gel pieces to the same culture well 
containing EGM-2 medium.  
C.1.6) Use the animal surgical facility to sedate the animal (5-6 week old NOD/SCID 
mice) by administrating isoflurane anesthesia. Shave the lower part of abdomen and 
thoroughly clean the surgical site with alcohol pads.  
C.1.7) Using sterile sharp iris scissors to make an approximately 5 mm incision in the 
lower quadrant of the abdomen, exposing the subcutaneous space between the skin and 
abdominal muscle. Perform blunt-dissection through the dermal layer from the abdominal 
muscle to create a 15-20 mm wide pocket leading superior into the upper abdominal 
quadrant. Repeat similar procedure to create similar open pocket in another side of the 
same mouse abdomen.  
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C.1.8) Insert one half piece of gel into one side of abdominal pocket and another half 
piece of gel into another side of the abdominal pocket by lifting the dermal layer just 
caudal to the incision.  
C.1.9) After insertion of gels, close each incision with 2-3 stitches using 5-0 
polypropylene suture on a cutting needle. Appropriately label the cage cards and perform 
post-surgical monitoring and analgesia as per the institutional and protocol requirements 
and allow 14 days for cells in these implanted gels to generate de novo vasculature.  
C.1.10) Finally, harvesting of gel implants is typically performed 14 days after 
implantation after euthanizing the mouse.  
C.1.11) Swab the abdominal area with alcohol pads and cut the abdominal skin caudal to 
the original incision line. Carefully, dissect out the implant by excising a flap of skin 
caudal to the probable location of the gel. Excise the implant by cutting circumferentially 
around the gel then place in zinc fixative (BD Biosciences, follow manufacturer’s 
recommendation for optimal results) and allow them to fix for 1-2 hours at room 
temperature.  
C.1.12) Prepare the paraffin-embedded gels using standard histochemical protocols and 
prepare 5 µm sections on glass slides to perform staining with hematoxylin and eosin, 
anti-human CD31 or anti-mouse CD31 to visualize the vasculature within the gel. ECFCs 
undergo de novo vasculogenesis to generate humanized vessels in cellularized gel 
implants inserted into immunodeficient mice for 14 days[2, 5, 51]. 
 
Representative Results  
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Using this ECFC derivation technique we have observed out-growth of primary colony 
formation as early as day 5 (Fig. 1). The out-growth ECFC colonies exhibited typical 
cobblestone appearance and gave rise to >40 population doublings upon long term 
expansion after colony pickup by cloning. Expanded colonies expressed endothelial 
antigens, but did not express hematopoietic antigens (Fig. 2). Importantly, they displayed 
a complete hierarchy of clonal proliferative potential at a single cell level (Fig. 3). 
Moreover, ECFCs formed humanized blood vessels that are perfused with host RBCs 
when implanted into immunodeficient mice[2, 3, 5, 51] (Fig. 4). 
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Figure 1. Isolation of mononuclear cells (MNCs) from cord blood and outgrowth of 
endothelial colony forming cells (ECFCs) from cultured MNCs. MNCs isolated from 
the buffy coat layer during Ficoll-Pague density gradient separation of cord blood cells. 
Isolation of buffy coat layer to culture MNCs on rat-tail collagen I (BD Biosciences) 
coated plates results in outgrowth of ECFC colony in 5 to 14 days. The outgrowth ECFC 
colony (indicated by arrow heads) displayed a cobblestone morphology[1]. 
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Figure 2. Representative in vitro phenotypic assessment of endothelial and 
hematopoietic cell surface antigen expression. Immunophenotyping of cord blood-
derived ECFCs revealed that ECFCs expressed typical endothelial antigens CD31, CD34, 
CD144, CD146, Flt-1, Flk-1, Flt-4, and Nrp2 but did not express typical hematopoietic 
antigens CD45, CD14, CD11b, cKit, CXCR4 or AC133[1, 2].  
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Figure 3. Representative in vitro quantitation of the clonogenic and proliferative 
potential of CB derived ECFCs. (A) cord blood-derived ECFCs display clonal 
proliferative potential with a hierarchy of colonies ranging from clusters of 2-50 cells up 
to colonies of >2001. (B) Micrographs of hierarchy of colonies (colonies stained with, 
Sytox, a green fluorescent nuclear dye) obtained after cord blood-derived ECFCs were 
cultured at a single cell level for 14 days. Scale bar represents 100µm[1, 2]. 
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Figure 4. Representative in vivo functional characterization of cord blood-derived 
ECFCs. (A) H&E staining of cord blood-derived ECFC containing cellularized gel 
implants indicated microvessel (filled with host RBCs) formation in collagen-fibronectin 
gel after 14 days of implantation. (B) Anti-human CD31 staining (brown staining) further 
confirms the human origin of these vessels.   
A
B
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Discussion:  
Phenotypic and functional characterization of putative endothelial progenitor cells is 
important to identify the bona fide ECFCs that are capable of clonally and serially re-
plating in culture and give rise to durable and functional implantable blood vessels in 
vivo. Human umbilical cord blood is enriched with ECFCs and the concentration of these 
circulating cells declines with aging or disease. Recent studies suggest that ECFC may 
play important roles in vascular repair or regeneration in situations of vascular injury, 
myocardial infarction, or retinopathy[18, 21, 56].  
Here, we have described simple and efficient methodologies for the derivation, cloning, 
expansion, and in vitro as well as in vivo characterization of ECFCs from human 
umbilical CB. These approaches enable researchers to identify and isolate bona fide 
EPCs from CB which possess clonal proliferative potential and in vivo vessel forming 
ability. 
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Chapter II: Derivation of Endothelial Colony Forming Cells from Human 
Embryonic Stem Cells 
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Introduction 
Endothelial dysfunction with resulting atherosclerosis is a fundamental cause of 
peripheral arterial disease (PAD) in a large percentage of elderly individuals. 
Development of critical limb ischemia (CLI) in patients with PAD is associated with 
adverse events such as stroke and myocardial infarction[57-60]. Circulating endothelial 
progenitor cells (EPCs) are rare but normal components of circulating blood[49] that are 
implicated in the repair of damaged blood vessels such as those found in patients with 
PAD. Endothelial colony forming cells (ECFCs) represent those rare circulating EPCs 
with robust clonal proliferative potential that display intrinsic in vivo vessel forming 
ability[1-3]. While ECFCs form durable and functional blood vessels in vivo, they are 
rare in peripheral blood (1/107-108 peripheral blood mononuclear cells) and their number 
tends to decline with age and disease[1]. In elderly patients and subjects with PAD, these 
cells may become prone to replicative senescence lacking proliferative potential, thus, 
rendering them impotent for vascular repair. Developing a protocol for the efficient 
derivation and expansion of ECFCs is crucial for their implementation in regenerative 
medicine. 
While human umbilical cord blood is enriched with ECFCs, use of these cells in 
patients with PAD as a cell therapy to repair endothelial dysfunction would constitute an 
allogeneic transplant.  This predisposes ECFCs for immune-rejection by the host. Human 
embryonic stem (hES) cell differentiation into the endothelial lineage has been reported 
to generate endothelial cells with mature endothelial phenotypes but low proliferative 
potential[44]; indeed there is no published evidence for derivation of ECFC (clonal 
proliferative endothelium) from hES cells. While human ES derived cells would also be 
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predisposed for host immune-rejection if not matched for MHC compatibility, identifying 
a differentiation pathway for ECFC from the well-studied hES lines is an appropriate 
starting point for future application to hiPS cells. While directed differentiation of hES 
cells into the endothelial lineage has been reported to generate endothelial cells with a 
mature endothelial phenotype possessing low proliferative potential, derivation of 
endothelial cells with cord blood ECFC-like properties (progenitor cells with clonal 
proliferative potential and in vivo vessel forming ability) from hES cells has not yet been 
reported. Papers have even reported that hES and IPS cells may be incapable of 
generating proliferative vascular cells[38, 61, 62]. 
In 2010, Rafii et al. reported that ECs could be derived from hES cells using a 
protocol which first involved the formation of EB bodies and isolation by CD144 
expression[62]. While this has been the gold standard protocol to date, reports also 
indicate that the TGFβ inhibitor had to be present throughout the culture period in order 
to restrict the EC from expressing alpha-smooth muscle actin (a protein more commonly 
seen in mesenchymal cells). Since CD144 has been reported to be expressed by 
mesoderm precursors, hematopoietic cells, and some cultured mesenchymal cells, we 
questioned whether the use of CD144 as a marker to enrich for hES-derived EC may lead 
to isolation of cells of many lineages.  
In 2009 a report by Cimato et al. reported that NRP-1 may be useful in identifying 
the emergence of endothelial cells during development from hES[33]. NRP1 is important 
in endothelial cell development and acts as a co-receptor for VEGF which helps to 
increase downstream signaling and enrich the commitment of cells to endothelial cell 
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fates[63]. Thus, we hypothesized that ECFCs may emerge from mesoderm precursors co-
expressing NRP-1 and CD31. 
Here we report that by modifying earlier reported protocols, with addition of a 
novel cell surface antigen selection, we have isolated endothelial cells with stable cord 
blood ECFC-like properties from hES. Compared to other sub-sets of sorted cells, only 
NRP-1+CD31+ cells exhibited ECFC properties. Our results show that NRP-1+CD31+  
isolated cells formed a homogenous cell monolayer with characteristic cobblestone 
morphology, exhibited clonal proliferative potential, generated capillary like structures 
when cultured on Matrigel, and formed robust in vivo vessels when in implanted in 
immune deficient mice. We speculate that this method of hES differentiation may also be 
effective in isolating ECFC from hiPS cells. 
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Materials and Methods 
Culturing of hES and IPS cells 
 H9 human embryonic stem cells were kindly provided by the Dr. Hal Broxmeyer 
lab (IUSM) and were maintained as previously published [64]. Cells were maintained in 
mTeSR1 complete media (Stem Cell Technologies, Vancouver, Canada) on Matrigel (BD 
Biosciences) in 10 cm2 tissue culture dishes at 37˚C and 5% CO2. After the plating of 
cells, media was changed on days 2, 3, and 4. Cells were routinely passaged on day 5. 
Passaging of hES and IPS cells 
Prior to passaging the hES cells, 10 cm2 tissue culture dishes were pre-coated with 
Matrigel for 1 hr. Tissue culture media from the hES cultures was aspirated and 4-5 mL 
of 2 mg/mL Dispase (Gibco, Grand Island, New York) was added to the plate. Cells were 
then incubated at 37˚C for 3-5 minutes until the edges of the colonies had lifted from the 
plate. The Dispase was aspirated from the plate and cells were gently washed with 
DMEM-F12 (Gibco) 3 times to remove any lingering Dispase. Fresh media was then 
used to harvest the cells from the plate using a forceful wash and scraping with a 5mL 
pipette taking care to avoid generation of excessive bubbles. Collected colonies were then 
centrifuged at 300xG for 5 min. During centrifugation, 7 mL of mTeSR1 complete media 
was added to Matrigel coated dishes to serve as culture medium for the pelleted colonies. 
The media was aspirated off of the centrifuged cells and then cells were resuspended in 
10 mL of mTeSR1 complete media and added to the Matrigel coated dishes. Cultures 
were checked for hES colony morphology quality on day 2. 
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Directed Differentiation 
After 2 days of culture in mTeSR1 media, hES cell cultures were directed toward 
the mesodermal lineage by pulsing with Activin A (10 ng/mL) under constant signaling 
of FGF-2 (Stemgent, Cambridge, Massachusetts), VEGF-165 (R&D, Minneapolis, 
Minnesota) and BMP4 (R&D) (10 ng/mL each). On day 1 Activin A containing media 
was removed and replaced with 8mL of Stemline II Media (Sigma, San Antonio, Texas) 
containing only FGF-2 and BMP4. Media was subsequently changed on days 3, 5, 7, and 
8 with 8 mL of differentiation media. On day 9 and thereafter media was changed with 10 
mL of differentiation media. This system was interrupted at any time for removal of cells 
for FACS analysis.  
 
Flow Cytometry 
To release the cells from the plate and the secreted ECM, TryplE (Life 
Technologies, Inc., Grand Island, New York) was added until the cells were just covered 
(5mL). The plates were then incubated at 37˚C for 5 minutes. In the presence of TryplE, 
cells were triturated using a 5 mL pipette and then deposited through a 0.4 micron filter 
into a 50 mL conical tube containing 10 mL of EGM2 (Lonza, Walkersville, Maryland). 
Tubes were then centrifuged at 300xG for 5 minutes. The supernatant was aspirated 
leaving behind the cell pellet. The pellet of cells was resuspended in 1 mL of EGM2.  
The cells were then counted and the appropriate amount of FCR block (Miltenyi 
Biotech, Auburn, California) was then added to the tube and incubated for 15 min as per 
manufacturer guidelines. A portion of the cell mixture was then withheld for an unstained 
control while another portion was stained with the appropriate antibodies as per their 
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recommended protocol.  Antibodies used included anti-human CD31 (CD31-FITC, clone 
WM59 from BD Pharmigen, San Jose, California, CAT # 555445), CD144 (CD144-PE, 
clone 16B1 from ebioscience, San Diego, California, CAT# 12-1449-82), and NRP-1 
(NRP1-APC, clone AD5176 from Miltenyi Biotech, CAT # 130-090-900). The cells and 
antibody were centrifuged at high speed for 30 sec. and the supernatant was removed. 
The pelleted cells were resuspended in EGM2 containing propidium iodide (3 ng/mL). 
The sample would then be immediately ready for analysis and remain on ice until 
analyzed. Samples were analyzed using a FACS Vantage (Becton Dixon) flow cytometer 
at a flow rate of 1/min. Compensation was set using cord blood derived ECFC color 
controls. Samples were analyzed using flow minus one (FMO) control analysis and the 
FloJo analysis software. 
 
Cell Culture of Sorted Cells 
Sorted cells were centrifuged at 300xG for 5 minutes then resuspended in 50% 
EGM2 and 50% complete Stemline II differentiation media. A 12 well plate was then 
coated with rat tail type I collagen (BD Biosciences) and plated with 2500 cells/well. 
After 2 days the media was changed to 75% EGM2 and 25% differentiation media. Then 
again after 2 days the media was changed to 100% EGM2. After approximately 1 week, 
ECFC colonies appear as tightly adherent cells with cobblestone morphology. Cloning of 
endothelial cell clusters was performed to isolate pure populations of highly proliferative 
endothelial cells. Cells were then split and replated at about 80% confluency and plated at 
10,000 cells/ cm2. Cells were then maintained in an endothelial culture system of cEGM-
2 media on collagen coated plates with media changes every other day. 
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In Vitro Network Formation Assay 
Matrigel coated 96 well plates (50 µl of Matrigel to each well) were prepared in 
triplicate. 10,000 ECFCs were prepared in 50 µl of EGM2 per well. 50 µl of EGM2 
containing cells were placed on top of the Matrigel coated surface. Next the plate was 
incubated overnight in 37˚C 5% CO2 (12-16 hours). On the next day the plate was 
removed and the network formation could be observed under phase contrast microscope. 
 
Immunohistochemistry and Western Blot Analysis 
  Twelve well plates with sterile glass coverslips on the bottom of the well were 
prepared and coated with type 1 rat tail collagen (BD Biosciences). 50,000 ECFC were 
added and cultured overnight. When cells formed a subconfluent monolayer they were 
processed for fixation using 4% (w/v) paraformaldehyde for 30 min and permeabilized 
with 0.1% (v/v) TritonX-100 in PBS for 5 min. After blocking with 10% (v/v) goat serum 
for 30 min, cells were incubated with primary antibodies; anti-CD31 (Santa Cruz), anti-
CD144 (ebioscience), anti-NRP-1 (Santa Cruz) and anti-a-SMA, (Chemicon) overnight at 
4˚C. Cells were washed with PBS, then incubated with secondary antibodies conjugated 
with Alexa-488 or Alexa-565 (Molecular Probe) and visualized by confocal microscopy 
after counterstaining with 2 g/ml DAPI (Sigma-Aldrich). The confocal images were 
viewed with Olympus FV1000 mpE confocal microscope using as objective 2-photon 
and Olympus uplanSapo 60xW/1.2NA/eus. All the images were taken at room 
temperature. 
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In Vivo Vessel Formation Assay 
Type 1 pig skin collagen master mix for gel implant was prepared by dissolving 
lyophilized collagens in 0.01 NHCL and neutralized with 10x PBS and 0.1 N sodium 
hydroxide to achieve neutral pH (7.4) and final collagen concentrations ranging from 0.5 
to 2.75 mg/ml[65]. The master mix was then mixed with the desired cell number 
(500,000 cells/ 250 microliter gel) in a 48 well tissue culture plate. The gel was allowed 
to solidify for 30 minutes at 37˚C and 5% CO2 and then 500µl of EGM2 was added. The 
cells then incubated overnight in 37˚C 5% CO2 (16-18 hours). The plate was taken the 
next day for implantation into NOD/SCID mice flanks. Detailed information on 
preparing, implanting, and removing gels after 14 days can be found in JOVE [66]. After 
removing gel after 14 days the gel was fixed with 4% paraformaldehyde and samples 
were processed for immunohistochemistry by a pathology laboratory for H&E staining 
and rat antihuman-CD31 monoclonal staining antibodies which do not cross react with 
host murine cells. 
 
Biostatistics 
All experiments were performed 3 times in triplicate and data are represented as mean + 
standard deviation for statistical comparison. Significance of differences was assessed by 
an unpaired t-test at p <0.05. 
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Results 
Endothelial cells derived from hES cells using existing published protocols exhibit 
low proliferative potential and lack properties of cord blood ECFC 
Human endothelial cells have been derived from hPS cells using a variety of 
methods. One approach is to promote differentiation of hPS through co-culture with OP9 
stromal cells[32, 37-39, 41] or mouse embryonic fibroblasts[61]. Another more recent 
approach seeks differentiation of hPS through embryoid body (EB) formation[30, 31, 33-
36, 40, 42, 44, 45, 67, 68] followed by application of various growth factors and/or 
receptor signaling pathway inhibitors to promote endothelial cell differentiation. While 
each method provides emergence of endothelial cells from the differentiated hPS cells, 
many of these studies failed to examine or discuss the proliferative potential of the 
endothelial cells produced or if mentioned, the endothelial cells were reported to possess 
very low proliferative potential[34, 43, 44] and to undergo cell senescence after only a 
few passages[45]. Indeed, none of the prior reports for the differentiation of endothelial 
cells from hPS described cells that appeared to display the clonal proliferative potential, 
replating capacity, or in vivo vessel forming ability of human cord blood ECFCs. 
Therefore, we sought to determine whether endothelial cells derived via the EB formation 
method of hES differentiation produces endothelial cells that possess cord blood ECFC 
properties. After 7 days of differentiation through EB formation, KDR+NRP-1+ cells were 
sorted and cultured in endothelial media as described[33]. When sorted cells were 
expanded, we found early passage cells (P.1) gave rise to a heterogeneous population of 
cells (Fig. 5), where only a portion of cells appeared to display an endothelial cell 
morphology. When these cells were further expanded (p.4), the cultures became 
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predominantly comprised of cells with a fibroblastic-like appearance and little endothelial 
cobblestone formation (Fig. 5). When these cells were characterized for endothelial 
surface antigen expression using flow cytometric analysis, a heterogeneous pattern of 
CD31, CD144, and CD146 expression was exhibited (Fig. 5) with only a portion of the 
cells expressing each of these antigens. Similarly when these cells were analyzed for 
ability to form vascular like networks on Matrigel they formed vascular like networks 
with numerous smaller incomplete branches that were sprout-like in appearance (Fig. 5). 
When we analyzed these cells (passage 3 to 4) for clonal proliferative potential we scored 
the outcomes as single cells that did not divide or divided to form colonies of 2-50 
(ECFC clusters), 51-500 (low proliferative potential ECFC; LPP-ECFC), 501-2000 (LPP-
ECFC), or >2000 cells (high proliferative potential-ECFC; HPP-ECFC). Less than 2% of 
the EB-derived cells gave rise to HPP-ECFC (Fig. 6). More of the EB-derived 
endothelial cells gave rise to LPP-ECFC (Fig. 6).  Most of the EB-derived endothelial 
cells did not divide or give rise to ECFC clusters (Fig. 6). These patterns of ECFC colony 
formation were significantly different from the pattern displayed by single endothelial 
cells derived from CB-ECFC colonies (Fig. 6). We were unable to expand the EB-
derived endothelial cells beyond passage 7 without them becoming senescent or drifting 
into a non-endothelial fibroblastic phenotype and the endothelial cells at passage 5 failed 
to give rise to human blood vessels in vivo upon implantation (Fig. 5).  
 
 
Endothelial lineage differentiation of human embryonic stem (hES) cells results in 
generation of subsets of cells that differ in phenotype and proliferative potential  
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Using a more recently published 2 step endothelial differentiation protocol that 
involves initial EB formation and then 2D adherent cell culture (with added growth 
factors)[66], we next sought to determine whether endothelial lineage differentiation of 
hES cells would give rise to different subsets of endothelial cells, including a subset 
displaying ECFC properties. Based upon the known importance of vascular endothelial 
growth factor (VEGF) signaling pathway in the emergence of endothelial cells both 
during development[69-71] and during endothelial lineage differentiation of hES 
cells[33], we utilized neuropilin-1 (NRP-1) as one of the endothelial markers for 
identifying emergence of ECFCs from hES cells. NRP-1 is a VEGF co-receptor and 
Semaphorin 3A binding multifunctional protein expressed in various tissues including 
endothelial cells, vascular smooth muscle cells and lymphocytes[72]. While the role of 
NRP-1 in vasculogenesis is unknown, a double knock out of NRP-1 and NRP-2 in mice 
leads to an embryonic lethal phenotype similar to that of the VEGFR-2 knockout[73, 74]. 
NRP-1 and NRP-2 double knockout mice die at day 8.5 and display an avascular yolk 
sac[73]. Conversely, exogenous over-expression of NRP-1 has previously been shown to 
form excess capillaries and hemorrhages in the developing cardiovascular, brain, and 
limb regions of the chimeric mouse embryos[75]. Since NRP-1 has been suggested as a 
potential early marker for the endothelial lineage during hES cell differentiation[33], we 
hypothesized that NRP-1 expression early in hES differentiating down the endothelial 
lineage may identify the emergence of ECFCs. We generated hES (H9 line) EBs in 
suspension culture for 4 days, and seeded them on Matrigel coated dishes for 10 days as 
described[34]. Cells were harvested and analyzed using antibodies that recognize typical 
endothelial antigens (CD31, CD144, and CD146) and NRP-1 on days 0, 3, 6, 9 and 14, to 
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determine the kinetics of endothelial antigen expression during the differentiation 
protocol (Fig. 7). Cells co-expressing NRP-1 and CD31 (NRP-1+CD31+ cells) appeared 
on day 3 (0.17%) and increased overtime to peak at day 14 (1.6%) (Fig. 7). The different 
subsets of day 14 sorted cells were cultured in endothelial growth (EGM-2) media 
supplemented with TGFβ inhibitor (10 μM SB431542) for 2 weeks, as TGFβ inhibition 
has been reported to promote endothelial lineage differentiation from hES cells and to 
prevent the cells from transitioning to a mesenchymal fate[34]. All of these subsets 
survived in endothelial growth media and formed confluent monolayers of cells. While 
most hES-derived subsets formed incomplete capillary-like networks upon plating in 
Matrigel, NRP-1+CD31+ cells formed complete structures similar to those exhibited by 
CB derived ECFCs, (Fig. 8). When the endothelial subsets were seeded at a clonal level, 
more than 55% of NRP-1+CD31- cells and more than 70% of NRP-1-CD31+ (Fig. 7) cells 
divided and displayed a near complete hierarchy of clonal proliferative potential. 
However, few clones from each of the sorted hES derived endothelial subsets gave rise to 
HPP-ECFC (the most proliferative population derived from a single input cell). In 
contrast, all of the NRP-1+CD31+ plated cells divided and many clones (37%) formed 
HPP-ECFC, indicating that the NRP-1+CD31+ cell subset possesses ECFC properties 
with the highest clonal proliferative potential (Fig. 7). Thus co-expression of NRP-1 and 
CD31 in hES-derived cells undergoing endothelial differentiation (EB plus 2D protocol) 
identifies a progenitor subset that gives rise to endothelial cells with high clonal 
proliferative potential and angiogenic activity, but only if cultured in the continual 
presence of TGF-β inhibition (upon removal of the TGF-β inhibitor, cells ceased to 
proliferate, changed morphology from cobblestone to spindle elongated shapes, and 
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upregulated alpha-smooth muscle actin [α-SMA] a marker of mesenchymal 
differentiation similar to previously published data)[66].  
 
Novel ECFC protocol generates NRP-1+CD31+ cells from hES cells at higher 
frequency and does not require TGFβ inhibition  
 While a two-step, EB plus 2 dimensional endothelial differentiation protocol was 
able to give rise to NRP-1+CD31+ cells with clonal high proliferative potential, this was 
an inefficient process that generated heterogeneous EBs containing cells from all germ 
layers, required persistent presence of TGF-β inhibition to maintain the endothelial fate, 
and yielded a low percentage of NRP-1+CD31+ cells. Therefore, we sought to develop an 
endothelial lineage differentiation protocol that did not require EB formation and TGF-β 
inhibition but ensured early preferential differentiation of hES cells towards the 
mesodermal lineage to give rise to an increased yield of the NRP-1+CD31+ cells 
possessing ECFC properties. Human PS cells were cultured on Matrigel coated plates in 
mTeSR1 media for two days as described[76]. To induce endothelial lineage 
differentiation, mTeSR1 media was replaced with Stemline II media supplemented with 
10 ng/mL Activin-A, BMP4, VEGF165 and FGF2  on day 0 of differentiation. The tissue 
culture media was replaced the following day with fresh Stemline II media supplemented 
with 10 ng/mL BMP4, VEGF165 and FGF2. Cells were harvested at day12 and analyzed 
for cells co-expressing CD31, CD144 and NRP-1 antigens (Fig. 9). Using this protocol, 
we were able to harvest an average 2% NRP-1+CD31+ cells from hES cells (Fig. 10). We 
directly compared NRP-1+CD31+ and NRP-1-CD31+ cells for their ability to give rise to 
endothelial colonies and total cell expansion after 7 days of plating in an endothelial 
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transitioning media. When we plated 2500 NRP-1+CD31+ and NRP-CD31+ sorted cells in 
a well of a 12 well collagen coated plate, NRP-1+CD31- cells gave rise to significantly 
fewer endothelial colonies compared to colonies generated from plated NRP-1+CD31+ 
cells (Fig. 11). Also, the morphology of NRP-1+CD31+ progeny was homogenous and 
cobblestone in appearance (Fig. 12; top right panel), whereas, we found a heterogeneous 
cell population within the colonies obtained from NRP-1-CD31+ cells. Finally, we 
counted the total number of cells in these colonies after 7 days of culture and found a 
significant (15 fold) increase in cultures initiated with NRP-1+CD31+ cells compared to 
CD31+NRP- cells (Fig. 11). Further we performed immunocytochemistry analysis of both 
NRP-1+CD31+ and NRP-CD31+ sorted cells using antibodies recognizing the endothelial 
antigens CD31, CD144 and NRP-1 and the non-endothelial antigen α-SMA. Cells grown 
from the NRP-1+CD31+ sorted fraction exhibited surface co-expression of CD31 and 
NRP-1 (yellow arrows, Fig. 12; top left panel) and uniform expression of CD144 but 
completely lacked expression of α-SMA (white arrows, Fig. 12; top middle panel). 
However, in cells produced from the CD31+NRP- sorted fraction, few cells expressed 
CD144 and almost the entire cell subset expressed α-SMA (arrows, Fig. 12; top right 
panel), indicating a drift away from an endothelial phenotype. Finally we examined hES 
derived NRP-1+CD31+ and NRP-CD31+ cells to determine the clonal proliferative 
behavior of the cells and found that both cell subsets displayed some evidence of clonal 
proliferative potential (Fig. 12). While more than 27% of cells derived from the 
CD31+NRP- subset failed to divide, 45% formed endothelial clusters, 25% formed LPP-
ECFC and a mere 1% formed HPP-ECFC colonies. In contrast, only 2% of the NRP-
1+CD31+ cell subset failed to divide, 4% formed endothelial clusters, 45% formed LPP-
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ECFC, and 48% formed HPP-ECFC (Fig. 12). Furthermore, NRP-1+CD31+ cells formed 
highly branching capillary-tube like structures (Fig. 13), whereas, CD31+NRP- cells 
formed incomplete capillary-like networks when plated on Matrigel (Fig. 13). Finally, 
hES derived NRP-1+CD31+ cells produced endothelial cells with robust in vivo vessel 
forming ability that inosculated with the host murine vessels (Fig. 13) similar to that of 
CB-ECFCs previously described[2, 5]. Importantly, NRP-1+CD31+ cells did not induce 
teratoma formation after more than 3 months of implantation into immunodeficient mice 
in more than 24 animals (data not shown). However, CD31+NRP- cells failed to generate 
functional human blood vessels (documented by the intraluminal presence of murine 
RBCs), indicating lack of de novo vessel forming and/or inosculating ability (Fig. 13). 
Collectively, ECFC protocol day12 derived NRP-1+CD31+ cells exhibited homogenous 
cobblestone morphology, expressed typical endothelial antigens, formed capillary-like 
networks on Matrigel in vitro, exhibited high clonal proliferative potential, and produced 
robust in vivo vessels filled with host RBCs. Therefore, the day 12 hES derived NRP-
1+CD31+ cell fraction produces endothelial cells that possess properties similar to cord 
blood ECFC. 
 
NRP-1+CD31+ cells emerge as clusters of cells lacking a-SMA expression and upon 
isolation and culture undergo extensive expansion, maintain stable endothelial 
phenotype, and ultimately become senescent after long-term culture expansion   
 While hESD12 differentiated cells possess complete ECFC properties, the earliest 
emergence of cells co-expressing CD31 and NRP-1 during hES differentiation had not 
been determined. Cimato et al. reported that NRP-1 is not expressed in undifferentiated 
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hES cells. Our data also revealed that day 0 undifferentiated hES cells did not co-express 
CD31 and NRP-1 (Fig. 10). We determined that NRP-1+CD31+ cells start to appear at 
day 4 in hES cells undergoing ECFC differentiation (Fig. 10). The percentage of NRP-
1+CD31+ cells progressively increased over time and reached the highest levels at day 12  
of differentiation(Fig. 10). Morphological analysis of hES cells undergoing ECFC 
differentiation at day 6, day 9, and day 12 revealed emergence of cobblestone like 
morphology at day 9 and day 12 (Fig. 14). Also, IHC revealed that NRP-1+CD31+ cells 
emerge as a cluster of cells within the mass of differentiating cells (Fig. 15). Further 
examination revealed that while hES-derived NRP-1+CD31+ cells emerged as early as 
day 3 of differentiation, the endothelial cells derived at day 12 gave rise to ECFC that 
exhibited the highest frequency of co-expression of the typical endothelial antigens 
without expression of the mesenchymal antigen α-SMA (Fig. 14,15).  
 Next, we sought to examine the ability of hES-ECFCs to undergo long term 
expansion by continually culturing them in extended endothelial culture until they began 
to exhibit evidence of replicative senescence. Primary cells do not proliferate indefinitely 
but instead undergo senescence after long term in vitro culture[77]. In extended 
endothelial culture, we were able to expand both hES-ECFCs and CB-ECFCs up to 18 
passages (Fig. 16). While the majority of hES-ECFCs and CB-ECFCs at passage 18 were 
senescent and were exhibiting characteristics of mortal primary cells[77], they still 
maintained an endothelial cobblestone morphology. We also detected continued 
homogenous expression of endothelial CD31, NRP-1 and CD144 antigen expression in 
these cells at passage 18 (Fig. 16). Collectively, this suggests that hES-ECFCs maintain a 
44 
stable endothelial phenotype throughout long term expansion culture but like any primary 
cell type, eventually exhibit replicative senescence.  
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Figure 5. Characterization of EB derived hES-endothelial cells. (A) top row 
Morphology of endothelial cells isolated at day 7 of EB cultured in the endothelial 
conditions. Cells exhibit heterogeneous morphology. (B) second row Endothelial cell 
surface marker profile of isolated cells at D7 of differentiation. (C) bottom row, left panel 
The day 7 cultured endothelial cells plated on Matrigel exhibit short numerous branches 
that do not form complete capillary-like networks. (D) bottom row, right panel Images of 
anti-human stained CD31 labeled endothelial cells in sections of implanted gels 
recovered after two weeks of residence in immunodeficient mice, display the presence of 
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human endothelial cells but lack vascular lumen formation (no presence of murine red 
blood cells to indicate inosculation of the human vessels to the mouse circulation). 
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Figure 6. EB derived hES-endothelial cells are largely non-dividing cells and LPP-
ECFC. EB derived cells exhibit a largely non-dividing single cell activity with some 
endothelial clusters, limited LPP-ECFC, and few HPP-ECFC. Human cord blood ECFC 
display a significantly different pattern with large numbers of LPP-ECFC and HPP-
ECFC. 
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Figure 7. CD31 and NRP-1 expression in EB differentiation of hES-endothelial cells 
and their proliferative potential. (A) top row Day 0 hES cells are negative for CD31 
NRP-1 double positive cell expression. Double positive cells begin to emerge at day 3 
and the maximum percentage is observed on day 14. (B) bottom graph Double positive 
NRP-1 and CD31 expressing cells generated from the EB protocol exhibit a largely HPP 
when analyzed in a single cell assay consistent with CB-ECFCs but require the aid of a 
TGFβ inhibitor. 
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Figure 8. EB derived NRP-1+ CD31+ hES-EC exhibit characteristic CB-ECFC 
morphology in vitro and capillary-like network forming ability on Matrigel coated 
plates. Cells derived from the EB protocol generate NRP-1+ CD31+ cells that exhibit 
characteristic EC cobblestone morphology and in vitro capillary-like network formation 
similar to control cord blood ECFC, but in the presence of TGF- inhibitor. 
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Figure 9. Optimization of hES differentiation into ECFC. Differentiation of hES cells 
was initiated 2 days after plating and denoted as day 0. Cytokines were distributed in 
defined media until day 12. On day 12 cells were sorted for CD31+ CD144+ NRP-1+ 
phenotype. 
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Figure 10. Kinetic Analysis of H9 directed Differentiation. Analysis of CD31+ NRP1+ 
CD144+ cells present during differentiation. Cells isolated prior to day 10 failed to meet 
the criteria of an ECFC and did not form vessels in vivo. Day 12 shows the optimal time 
point for efficiently isolating the putative ECFCs based on NRP1 expression. Samples 
tested at days 6 and 8 failed to generate cells with ECFC-like properties (not shown). 
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Figure 11. Efficiency of expansion of hES-ECFCs. (A) left graph Colonies consistently 
emerge from isolated CD31 NRP-1 double positive cells. (B) right graph Fold expansion 
is much greater in double positive isolated cells.  
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Figure 12. CD31 NRP-1 double positive isolated cells do not express α-SMA and 
replicate CB-ECFC proliferative potential. (A) top row Previous methods had 
difficulty restricting SMA expression which is not a characteristic of endothelial cells or 
ECFCs. NRP-1 CD31 double positive cells so not express SMA, however NRP-1+CD31- 
cells do not. (B) bottom graph Double-positive hES-ECFCs exhibit textbook CB-ECFC 
proliferative hierarchy compared to cord blood ECFC (control). 
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Figure 13. CD31 NRP-1 double positive isolated cells form in vitro networks and 
vessels in vivo. (A) While in vitro network formation of the Nrp-1+CD31+ cells is 
robust, NRP-1+CD31- cells fail to form complete networks. (B) Murine red blood cell 
perfused vessels stained with anti-human CD31 coupled with H&E staining shows the 
ability of Nrp-1+CD31+ but not NRP-1+CD31- hES-ECFCs to integrate into the host 
vasculature system 
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Figure 14. H9 hESC derived ECFC in vitro analysis of phenotype and network 
formation. (A) Top Row FACS was used to isolate putative ECFCs at different time 
points during differentiation using CD31 (x-axis) and NRP1 (y-axis). (B) Middle Row 
Monolayer of isolated putative ECFCs at different time points. (C) Bottom Row Matrigel 
network in vitro formation of isolated and expanded putative ECFCs indicate increased 
ability to form networks towards day 12.  
  
56 
 
Figure 15. H9 hESC derived ECFC immunohistochemical kinetic analysis of 
endothelial antigen expression. Differentiation was initiated in 12 well tissue culture 
dishes and fixed at varying time points. The wells were then stained for endothelial 
antigens and α-SMA. (A) top row unstained control (B) middle Row NRP1 staining 
indicates the increase in expression towards day 12. CD31 staining indicates the increase 
in expression towards day 12. (C) bottom Row αSMA staining indicates the absence of 
expression at day 12. CD144 staining indicates the increase in expression at day 12 in a 
pattern reminiscent of capillary-like structures.  
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Figure 16. Late Passage Analysis of hESC derived ECFCs. (A) FACS analysis of late 
passage ECFCs isolated from hESC show decline in NRP1 expression but maintenance 
of endothelial marker CD31. (B) Late passage isolated ECFCs retain the ability to form 
vessels in vivo in immune compromised mice despite loss of NRP1 expression.  
  
58 
Discussion 
We have established a method to reproducibly derive and isolate a homogenous 
and stable population of endothelial cells possessing umbilical cord blood ECFC-like 
properties. NRP-1+CD31+ cells formed a homogenous monolayer with characteristic 
cobblestone appearance, exhibited high clonal proliferative potential, demonstrated 
angiogenic behavior by forming complete capillary like structures when cultured on 
Matrigel, and formed robust in vivo inosculated vessels when implanted in immune 
deficient mice. These hES-derived ECFCs were stable and did not transition to non-
endothelial cells over prolonged culture (18 passages) and could expand to over a trillion 
endothelial cells in less than 3 months of culture.  
Timing is essential in the derivation of cell lineages from hES cells. Because of 
this we developed a detailed protocol and optimized the timing of growth factor delivery 
to most efficiently isolate ECFCs using the novel marker NRP-1. We found that by 
optimizing the timing of media alone we were able to substantially increase the efficiency 
of isolation using this marker. The stepwise differentiation protocol and the use of the 
double positive expression of NRP-1 and CD31 permitted isolation of cells with ECFC 
properties for the first time. While endothelial cells have been isolated from human 
pluripotent cells on many occasions previously, the cells derived failed to display 
persistent high proliferative potential and were noted to reach senescence after relatively 
few passages. Some previously reported protocols also required TGF-β inhibition both 
for the derivation and maintenance of a stable endothelial cell phenotype from 
differentiated hPS cells[34]. ECFCs generated from our methods exhibit a stable 
endothelial phenotype and display a complete hierarchy of clonal high proliferative 
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potential and form robust in vivo functional human vessels that inosculate with host 
blood vascular system in the complete absence of TGF-β inhibition. Our ECFC 
differentiation protocol yields one NRP-1+CD31+ ECFC per each input hESc after 12 
days of differentiation. More importantly, upon expansion, these NRP-1+CD31+ cells 
generate stable highly proliferative potential cells that can undergo long term expansion 
reaching a ratio of hES/ECFC: 1 to 1.1x108 in less than 3 months of culture. This highly 
efficient output of functional endothelial cells contrasts with reported yields of 0.6[31], 
7.4[34] and 11.6[78] endothelial cells from differentiated hPS cells using other published 
protocols. Thus, our method is highly scalable for potential clinical application and can 
generate cells sufficient for permitting future clinical trials to regenerate the deficient 
microvasculature in patients with cardiovascular diseases such as PAD and CLI. 
 Another key factor in the feasibility of implementation in clinical trials is not only 
efficacy of the treatments but the potential adverse effects associated with them. The 
ECFC derived in our protocol are not transformed which is shown by their normal 
behavior in the characterization of their ECFC qualities. In addition, the cells senesce at 
comparable passages as CB-ECFCs which indicates that telomere and telomerase activity 
have not been altered in the directed differentiation of hES-ECFCs. Thus, our culture 
derived cells are mortal in behavior in vitro and in vivo.  
 In no instance did these differentiated cells form a teratoma, a benign growth 
which displays differentiated cell types from all 3 germ layers, when implanted in 
immunocompromised mice. This proves that these cells are no longer undifferentiated 
and have assumed a specified state (ECFC state) since all hES cells form teratomas upon 
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injection as pluripotent cells. This is a key factor which helps to ensure that this cell type 
when administered to patients would be only positive in nature. 
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